LOGIN  |  REGISTER
Chimerix

List of Medical Device Stocks

Company
Last Trade
Change
Volume
Shares Out
Market Cap
US$ 104.51
0.46 0.44
3.42M
1.74B
US$ 181.850B
US$ 289.10
-0.28 -0.10
725,037
379.90M
US$ 109.830B
US$ 310.42
-1.14 -0.37
1.13M
352.07M
US$ 109.290B
US$ 79.35
-0.20 -0.25
6.23M
1.33B
US$ 105.540B
US$ 54.95
-0.08 -0.15
4.29M
1.46B
US$ 80.230B
US$ 232.30
-1.24 -0.53
1.65M
290.40M
US$ 67.460B
US$ 69.18
0.92 1.35
5.80M
606.50M
US$ 41.960B
US$ 71.99
0.09 0.13
609,763
491.80M
US$ 35.400B
US$ 342.24
1.05 0.31
388,549
73.99M
US$ 25.320B
US$ 117.30
0.01 0.01
1.31M
208.98M
US$ 24.510B
US$ 162.87
-0.62 -0.38
507,032
147.09M
US$ 23.960B
US$ 200.50
-1.49 -0.74
483,744
98.80M
US$ 19.810B
US$ 36.15
-0.38 -1.04
3.09M
507.32M
US$ 18.340B
US$ 221.23
4.62 2.13
1.32M
76.59M
US$ 16.940B
US$ 335.00
-9.95 -2.88
568,513
49.52M
US$ 16.590B
US$ 68.37
-0.85 -1.23
1.54M
240.00M
US$ 16.410B
US$ 194.66
0.12 0.06
871,855
69.83M
US$ 13.590B
US$ 26.28
0.24 0.92
846,310
436.70M
US$ 11.480B
US$ 231.08
-1.50 -0.64
182,960
46.99M
US$ 10.860B
US$ 67.97
-0.83 -1.21
756,233
138.41M
US$ 9.410B
US$ 159.27
-2.60 -1.61
467,551
55.83M
US$ 8.890B
US$ 224.04
0.85 0.38
276,699
38.60M
US$ 8.650B
US$ 304.13
-6.05 -1.95
213,607
24.06M
US$ 7.320B
US$ 31.88
-0.60 -1.85
3.53M
211.86M
US$ 6.750B
US$ 174.20
-0.89 -0.51
362,110
36.90M
US$ 6.430B
US$ 104.36
-2.12 -1.99
548,310
52.84M
US$ 5.510B
US$ 15.66
0.32 2.09
1.19M
350.86M
US$ 5.490B
US$ 46.51
1.18 2.60
1.64M
115.36M
US$ 5.370B
US$ 165.09
4.19 2.60
1.42M
29.52M
US$ 4.870B
US$ 84.84
1.58 1.90
221,428
50.74M
US$ 4.300B
US$ 69.82
0.21 0.30
417,610
57.75M
US$ 4.030B
US$ 23.45
-0.56 -2.33
3.76M
171.40M
US$ 4.020B
US$ 63.05
-0.26 -0.41
388,557
57.59M
US$ 3.630B
US$ 109.37
-0.21 -0.19
206,804
30.75M
US$ 3.360B
US$ 41.27
-0.04 -0.10
281,284
78.18M
US$ 3.230B
US$ 57.60
-0.64 -1.10
277,628
56.11M
US$ 3.230B
US$ 63.63
0.77 1.22
414,745
48.80M
US$ 3.110B
US$ 89.54
0.64 0.72
145,329
33.33M
US$ 2.980B
US$ 56.82
-1.06 -1.83
557,213
50.66M
US$ 2.880B
US$ 89.16
2.29 2.64
329,632
30.65M
US$ 2.730B
US$ 46.43
1.36 3.02
555,132
53.87M
US$ 2.500B
US$ 72.90
-2.21 -2.94
573,173
32.65M
US$ 2.380B
US$ 86.25
-1.24 -1.42
192,706
24.14M
US$ 2.080B
US$ 39.32
-0.65 -1.63
412,295
50.50M
US$ 1.990B
US$ 21.74
0.99 4.77
2.10M
83.23M
US$ 1.810B
US$ 12.71
0.14 1.11
1.08M
136.30M
US$ 1.730B
US$ 33.40
2.08 6.64
995,795
48.82M
US$ 1.630B
US$ 34.14
0.70 2.09
583,328
47.40M
US$ 1.620B
US$ 24.01
0.00 0.00
2.00M
65.21M
US$ 1.570B
US$ 12.50
-0.38 -2.95
954,581
106.86M
US$ 1.340B
US$ 34.97
0.81 2.37
474,090
35.86M
US$ 1.250B
US$ 54.65
0.03 0.05
166,452
22.26M
US$ 1.220B
US$ 8.28
0.30 3.76
746,293
136.39M
US$ 1.130B
US$ 10.68
-0.32 -2.91
2.08M
97.93M
US$ 1.050B
US$ 7.66
0.00 0.00
684,512
135.55M
US$ 1.040B
US$ 21.15
0.13 0.62
767,662
46.43M
US$ 981.990M
US$ 11.49
0.18 1.59
229,070
82.70M
US$ 950.220M
US$ 27.82
0.40 1.46
264,391
34.10M
US$ 948.660M
US$ 8.01
0.08 1.01
454,885
116.38M
US$ 932.200M
US$ 23.04
0.29 1.27
355,723
37.83M
US$ 871.600M
US$ 19.69
0.31 1.60
531,844
40.50M
US$ 797.440M
US$ 19.34
0.69 3.70
467,068
40.50M
US$ 783.270M
US$ 18.07
0.07 0.39
247,151
41.05M
US$ 741.770M
US$ 19.95
0.46 2.36
631,378
36.21M
US$ 722.390M
US$ 30.53
0.06 0.20
79,521
23.35M
US$ 712.880M
US$ 23.23
0.05 0.22
462,601
25.81M
US$ 599.570M
US$ 13.26
0.54 4.25
216,701
45.05M
US$ 597.360M
US$ 9.50
0.03 0.32
589,837
61.68M
US$ 585.960M
US$ 325.87
-1.12 -0.34
4,400
1.76M
US$ 573.530M
US$ 41.73
-0.05 -0.12
20,345
12.61M
US$ 526.220M
US$ 9.48
0.16 1.72
418,273
55.08M
US$ 522.160M
US$ 7.10
0.21 3.05
468,759
73.48M
US$ 521.710M
US$ 24.15
0.36 1.51
131,928
20.82M
US$ 502.800M
US$ 4.85
-0.15 -3.00
2.77M
103.58M
US$ 502.360M
US$ 11.79
0.02 0.17
171,451
38.31M
US$ 451.670M
US$ 11.76
0.39 3.43
750,533
36.76M
US$ 432.300M
US$ 9.72
-0.33 -3.28
499,723
38.95M
US$ 378.590M
US$ 2.96
0.06 2.07
81,614
120.76M
US$ 357.450M
US$ 6.10
0.21 3.57
593,801
57.73M
US$ 352.150M
US$ 13.65
0.49 3.72
106,063
25.55M
US$ 348.760M
US$ 0.63
0.003 0.48
1.41M
528.28M
US$ 333.340M
US$ 7.51
0.09 1.21
322,646
43.04M
US$ 323.230M
US$ 5.04
-0.07 -1.37
152,264
62.97M
US$ 317.370M
US$ 13.34
0.10 0.76
290,263
23.50M
US$ 313.490M
US$ 45.05
1.39 3.18
65,795
6.87M
US$ 309.490M
US$ 8.03
-0.02 -0.25
64,589
38.49M
US$ 309.070M
US$ 35.56
0.31 0.88
15,107
8.54M
US$ 303.680M
US$ 11.19
0.59 5.57
308,178
26.54M
US$ 296.980M
US$ 5.88
0.17 2.98
345,119
50.20M
US$ 295.180M
US$ 8.66
0.02 0.23
170,475
33.90M
US$ 293.570M
US$ 80.51
-1.49 -1.82
11,289
3.63M
US$ 292.250M
US$ 6.96
-0.07 -1.00
293,537
39.85M
US$ 277.360M
US$ 2.65
0.00 0.00
271,431
97.07M
US$ 257.240M
US$ 6.97
-0.30 -4.13
90,640
32.38M
US$ 225.690M
US$ 5.22
0.29 5.88
111,314
42.69M
US$ 222.840M
US$ 8.40
-0.09 -1.06
26,253
26.28M
US$ 220.750M
US$ 10.40
-0.02 -0.19
30,420
21.18M
US$ 220.270M
US$ 4.41
0.00 0.00
127,269
49.08M
US$ 216.440M
US$ 10.09
0.09 0.90
21,975
21.37M
US$ 215.620M
US$ 27.50
-1.52 -5.24
36,750
7.75M
US$ 213.120M
US$ 4.65
0.01 0.22
121,487
42.08M
US$ 195.670M
US$ 5.18
0.01 0.19
40,415
36.93M
US$ 191.300M
US$ 0.94
0.02 2.71
784,258
180.70M
US$ 170.540M
US$ 1.27
-0.05 -3.79
40,926
130.11M
US$ 165.240M
US$ 1.96
0.08 4.26
330,564
80.88M
US$ 158.520M
US$ 3.32
0.01 0.30
13,091
47.44M
US$ 157.500M
US$ 2.87
0.22 8.30
449,755
48.75M
US$ 139.910M
US$ 5.94
0.13 2.24
322,148
23.31M
US$ 138.460M
US$ 5.54
0.11 2.03
95,580
24.49M
US$ 135.670M
US$ 4.66
-0.13 -2.71
24,883
28.67M
US$ 133.600M
US$ 19.82
0.02 0.10
26,289
6.45M
US$ 127.840M
US$ 2.39
0.03 1.06
32,510
45.67M
US$ 108.920M
US$ 3.47
0.30 9.46
42,723
31.13M
US$ 108.020M
US$ 3.98
-0.31 -7.23
796,916
26.52M
US$ 105.550M
US$ 4.00
0.03 0.76
58,406
26.32M
US$ 105.280M
US$ 5.69
0.24 4.40
339,600
16.61M
US$ 94.510M
US$ 10.53
0.21 2.03
23,118
8.58M
US$ 90.350M
US$ 2.12
0.04 1.92
150,742
34.64M
US$ 73.440M
US$ 0.25
-0.0055 -2.15
238,437
280.57M
US$ 70.140M
US$ 0.26
0.00 0.00
756,416
264.32M
US$ 69.280M
US$ 1.20
0.00 0.00
60,898
56.54M
US$ 67.850M
US$ 2.98
0.11 3.83
221,666
22.05M
US$ 65.710M
US$ 16.76
0.63 3.91
4,868
3.55M
US$ 59.500M
US$ 1.37
-0.09 -6.18
16,789
42.88M
US$ 58.750M
US$ 1.28
-0.08 -5.88
182,035
44.44M
US$ 56.880M
C$ 0.86
0.01 1.18
18,000
65.03M
C$ 55.930M
US$ 2.57
0.07 2.80
55,534
21.55M
US$ 55.380M
US$ 3.09
0.00 0.00
0
17.59M
US$ 54.350M
US$ 2.59
-0.01 -0.39
19,179
20.76M
US$ 53.770M
US$ 0.71
-0.08 -9.62
435,182
71.05M
US$ 50.450M
US$ 3.78
0.05 1.20
85,447
13.32M
US$ 50.350M
US$ 0.94
-0.02 -2.39
10,587
51.03M
US$ 47.770M
US$ 2.92
-0.11 -3.63
39,714
16.25M
US$ 47.450M
US$ 1.03
0.01 0.98
244,521
45.64M
US$ 47.010M
US$ 1.47
0.02 1.38
233,499
31.97M
US$ 46.840M
US$ 5.38
0.30 5.91
22,849
8.57M
US$ 46.110M
US$ 1.92
0.13 7.26
813,638
23.95M
US$ 45.980M
US$ 2.28
0.06 2.70
563,801
20.02M
US$ 45.650M
US$ 2.76
0.02 0.73
39,195
16.25M
US$ 44.850M
C$ 0.19
-0.01 -5.13
25,000
228.46M
C$ 42.270M
US$ 0.76
-0.35 -31.85
83,845
55.68M
US$ 42.260M
US$ 0.27
-0.02 -5.50
781,517
155.27M
US$ 41.610M
US$ 1.12
-0.02 -1.32
1,885
37.09M
US$ 41.540M
C$ 0.41
-0.005 -1.22
35,000
101.40M
C$ 41.070M
US$ 2.07
0.08 4.02
56,010
19.55M
US$ 40.470M
C$ 0.34
0.01 3.03
13,500
118.47M
C$ 40.280M
US$ 0.67
-0.0099 -1.46
117,012
60.02M
US$ 40.210M
C$ 0.26
0.005 2.00
237,114
156.82M
C$ 39.990M
US$ 1.66
-0.02 -1.19
282,842
23.94M
US$ 39.740M
US$ 2.00
0.00 0.00
116,868
18.88M
US$ 37.760M
US$ 1.74
0.16 10.13
85,999
21.23M
US$ 36.940M
C$ 0.70
0.00 0.00
8,800
52.64M
C$ 36.850M
US$ 2.24
-0.05 -2.25
20,403
16.38M
US$ 36.660M
US$ 1.12
0.02 1.82
71,481
29.94M
US$ 33.530M
US$ 5.55
-0.02 -0.36
6,308
6.00M
US$ 33.300M
C$ 0.42
0.03 6.33
2,000
69.23M
C$ 29.080M
US$ 0.39
-0.0017 -0.44
93,514
73.38M
US$ 28.250M
US$ 0.32
-0.01 -3.64
239,857
88.11M
US$ 28.020M
US$ 2.26
-0.02 -0.88
46,231
11.25M
US$ 25.420M
US$ 2.19
0.11 5.29
62,157
10.48M
US$ 22.950M
C$ 0.12
0.00 0.00
33,500
194.28M
C$ 22.340M
US$ 1.47
-0.03 -2.00
95,455
14.23M
US$ 20.920M
US$ 15.31
-0.58 -3.65
212,300
1.33M
US$ 20.360M
US$ 0.05
0.00 0.00
190,567
371.00M
US$ 19.480M
US$ 0.55
-0.08 -12.63
42,832
35.05M
US$ 19.290M
US$ 0.89
0.007 0.79
251,727
21.65M
US$ 19.250M
US$ 1.11
0.05 4.72
31,006
16.82M
US$ 18.670M
US$ 0.01
0.0007 5.00
77,000
1.03B
US$ 15.140M
US$ 1.25
0.03 2.46
30,750
11.71M
US$ 14.640M
US$ 7.97
-0.08 -0.99
3,523
1.82M
US$ 14.500M
US$ 0.97
0.07 7.53
10,118
14.47M
US$ 14.010M
US$ 1.02
-0.0055 -0.54
70,171
12.32M
US$ 12.570M
C$ 0.22
-0.005 -2.22
169,500
56.99M
C$ 12.540M
US$ 3.07
0.08 2.68
8,800
4.06M
US$ 12.460M
US$ 2.16
0.13 6.42
9,889
5.72M
US$ 12.360M
US$ 1.97
-0.03 -1.50
32,646
6.14M
US$ 12.100M
C$ 0.06
0.01 20.00
54,000
188.08M
C$ 11.280M
US$ 0.38
-0.01 -2.99
42,733
29.95M
US$ 11.260M
US$ 1.08
-0.02 -1.82
19,090
8.77M
US$ 9.470M
US$ 0.55
-0.05 -8.33
66,780
16.40M
US$ 9.020M
US$ 0.12
0.00 0.00
0
73.90M
US$ 8.500M
US$ 0.70
-0.06 -7.35
226,686
11.96M
US$ 8.310M
US$ 0.10
0.01 11.11
166,551
81.73M
US$ 8.170M
US$ 0.52
0.02 4.89
64,482
15.27M
US$ 7.960M
US$ 0.16
-0.02 -10.50
7.39M
48.60M
US$ 7.790M
US$ 1.30
-0.04 -2.98
7,311
5.53M
US$ 7.190M
C$ 0.03
0.00 0.00
0
246.29M
C$ 6.160M
US$ 0.21
-0.03 -14.24
567,174
29.30M
US$ 6.090M
US$ 0.21
0.0003 0.14
45,321
28.90M
US$ 6.080M
US$ 0.11
-0.12 -53.26
210,064
54.28M
US$ 5.840M
US$ 7.13
0.35 5.16
12,739
708,247
US$ 5.050M
US$ 2.02
-0.07 -3.35
28,064
2.49M
US$ 5.030M
US$ 0.42
-0.04 -8.06
4,940
11.77M
US$ 4.960M
US$ 3.16
0.11 3.61
3,073
1.28M
US$ 4.040M
US$ 3.26
0.17 5.50
4,189
1.24M
US$ 4.040M
US$ 1.60
-0.06 -3.61
38,692
2.47M
US$ 3.950M
US$ 3.58
0.09 2.58
40,381
1.09M
US$ 3.900M
US$ 1.43
-0.06 -4.03
147,592
2.47M
US$ 3.530M
US$ 0.25
-0.01 -4.04
1.79M
13.14M
US$ 3.280M
US$ 0.47
0.0068 1.48
23,574
6.46M
US$ 3.020M
US$ 2.01
-0.04 -1.95
122,661
1.47M
US$ 2.950M
US$ 0.38
-0.02 -5.00
6,228
7.44M
US$ 2.830M
US$ 0.87
-0.0026 -0.30
22,565
3.14M
US$ 2.720M
US$ 0.58
-0.02 -3.51
11,707
4.53M
US$ 2.630M
US$ 0.30
-0.01 -4.64
658,431
8.73M
US$ 2.620M
US$ 0.30
0.00 0.00
0
8.48M
US$ 2.540M
US$ 1.07
-0.02 -1.38
14,363
2.05M
US$ 2.190M
US$ 0.57
-0.03 -5.73
126,870
3.26M
US$ 1.840M
US$ 0.42
-0.02 -4.32
173,075
4.27M
US$ 1.800M
US$ 1.13
-0.07 -5.83
78,403
1.04M
US$ 1.180M
US$ 0.001
0.00 0.00
297,250
471.50M
US$ 472K
US$ 0.02
0.0025 12.50
1,000
9.74M
US$ 219K
US$ 0.51
0.00 0.00
0
-
US$ -
C$ 1.25
0.00 0.00
14,800
-
C$ -

Latest News From Medical Device Stocks


Sight Sciences Announces the Acceptance for Publication of GEMINI 2, a Three Year, Prospective, Multicenter Trial Demonstrating Sustained, Significant IOP and Medication Reductions Enabled with the OMNI®...

Prospective, long-term trial results are consistent with the significant body of published clinical evidence demonstrating the durable safety and effectiveness of procedures enabled with the OMNI Surgical System technology MENLO PARK, Calif., Dec. 08, 2023 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences”), an eyecare technology company focused on developing and commercializing innovative technology intended to transform care and improve... Read more


Milestone Scientific Commences Sales of CompuFlo®  Disposables for Use in Neurostimulation Spinal Cord Implantation Procedures

Adoption of the technology at UTMB Health Clear Lake Campus Hospital follows successful evaluation process in these procedures—reporting 100% success CompuFlo helps minimize intraoperative cerebral fluid leakage and trauma to underlying nerve roots ROSELAND, N.J., Dec. 08, 2023 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE:MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, today reported... Read more


Milestone Scientific Announces Proposed Public Offering of Common Stock

ROSELAND, N.J., Dec. 08, 2023 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE:MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, today announced that it has commenced an underwritten public offering of shares of its common stock (the “Offering”). The Company also expects to grant to the underwriters a 45-day option to purchase up to an additional 15% of the shares of common stock offered in... Read more


CooperCompanies Announces Fourth Quarter and Full Year 2023 Results

SAN RAMON, Calif., Dec. 07, 2023 (GLOBE NEWSWIRE) -- CooperCompanies (Nasdaq: COO), a leading global medical device company, today announced financial results for its fiscal fourth quarter and full year ended October 31, 2023. Fourth quarter 2023 revenue of $927.1 million, up 9%, and up 9% organically. Fiscal year 2023 revenue of $3.6 billion, up 9%, or up 10% organically. Fourth quarter 2023 GAAP diluted earnings per share (EPS) of $1.70, up 29%. Fiscal 2023 GAAP... Read more


Haemonetics to Present at 42nd Annual J.P. Morgan Healthcare Conference

BOSTON, Dec. 7, 2023 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that Chris Simon, President and CEO, will present at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco on Tuesday, January 9, 2024 at 9:45am Pacific time. The public may access Mr. Simon's presentation here. The live webcast can also be accessed under the Events & Presentations section of the Company's Investor Relations website. The replay of the presentation... Read more


Delcath Systems Announces Publication by Independent Investigators of a Retrospective Analysis of Quality of Life in the Journal Melanoma Research

Retrospective Analysis of Changes in Patients with Metastatic Uveal Melanoma treated with Chemosat Hepatic Delivery System Results Support that Utilizing Delcath's HDS to Administer High-Dose Melphalan to the Liver Is Well Tolerated by Patients NEW YORK, Dec. 7, 2023 /PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced the publication of a... Read more


Ocumetics Announces Successful Completion of Animal Study Q1 2024 First in Human Study Planned

Calgary, Alberta – TheNewswire - December 7, 2023 - Ocumetics Technology Corp. (“Ocumetics”) (TSXV:OTC) (OTC:OTCFF) (FRA:2QBO), a pioneer in the field of ophthalmic innovation, proudly confirms the successful completion of its biocompatibility animal study, in preparation for its first-in-human study, anticipated to commence in Q1 2024 in the Dominican Republic. The biocompatibility of the Ocumetics accommodating intraocular lens (the “Ocumetics Accommodating Lens”)... Read more


AngioDynamics Completes Patient Enrollment in APEX-AV Study Assessing AlphaVac F1885 System in Treatment of Pulmonary Embolism

122 Patients Enrolled in Single-arm IDE Study; 30-Day Follow-up LATHAM, N.Y. / Dec 07, 2023 / Business Wire / AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and improving patient quality of life, today announced the completion of patient enrollment in the Acute Pulmonary Embolism Extraction Trial with the AlphaVac System... Read more


Perspective Therapeutics Announces First Patient Dosed in a Phase 1 Study of [(212)Pb]VMT-α-NET to Treat Refractory or Relapsed Neuroendocrine Tumors

First U.S. patient with refractory or relapsed SSTR2-positive neuroendocrine tumors treated with [212Pb]VMT-α-NET Preliminary data readout expected in second half of 2024 SEATTLE, Dec. 07, 2023 (GLOBE NEWSWIRE) --  Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), announced today that the first patient was dosed at the University of Iowa in an investigator-initiated Phase 1 trial evaluating the safety of [21... Read more


BrainsWay Announces Continued Expansion of Deep TMS™ in South Korea

BURLINGTON, Mass. and JERUSALEM, Dec. 07, 2023 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced expanded availability of its Deep Transcranial Magnetic Stimulation (Deep TMS™) technology in South Korea. After growing momentum over the past few years, recent sales are expected to bring BrainsWay’s installed... Read more


Microbot Medical Announces the Successful Completion of Its GLP Pivotal Pre-Clinical Study, a Critical Milestone for Its IDE submission to Commence Human Clinical Study

The final histopathology and lab report supplements previous positive Company findings. The results of the study will support the Company’s IDE submission to the FDA to commence its human clinical study. BRAINTREE, Mass., Dec. 07, 2023 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer of the innovative LIBERTY® Endovascular Robotic Surgical System, today announces the successful completion of its GLP pivotal pre-clinical study, done under the... Read more


Repligen Announces Private Convertible Transaction of $600 Million Principal Amount of 1.00% Convertible Senior Notes Due 2028 Through Exchange and New Subscription Agreements

WALTHAM, Mass., Dec. 07, 2023 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ: RGEN) today announced that on December 6, 2023, it entered into privately negotiated exchange and/or subscription agreements with certain holders of its outstanding 0.375% Convertible Senior Notes due 2024 (the “2024 Notes”) and certain new investors, pursuant to which Repligen will issue $600 million aggregate principal amount of 1.00% Convertible Senior Notes due 2028 (the “New Notes”).... Read more


Becton Dickinson Receives FDA 510(k) Clearance for Potentially Transformative Fingertip Blood Collection Device

BD MiniDraw™ Capillary Blood Collection System Enables Lab-Quality Blood Testing from Less Invasive Method than Venous Collection in More Convenient Locations FRANKLIN LAKES, N.J., Dec. 7, 2023 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced it has received 510(k) clearances from the U.S. Federal Drug Administration (FDA) for a novel blood collection device that obtains blood samples from... Read more


INVO Bioscience: NAYA Biosciences and ONK Therapeutics Announce Research Partnership to Advance Combination Therapy of FLEX-NK™ Bispecific Antibodies and Optimally Engineered Off-the-Shelf Natural Killer...

NAYA Biosciences and ONK Therapeutics to assess proof-of-concept and establish activity and feasibility of the combination of NAYA's FLEX-NK™ bispecific antibodies and ONK's optimally engineered natural killer (NK) cells for the treatment of cancer Partnership may be expanded to joint clinical development following successful completion of the initial research Combination therapy expected to improve response rate and address significant unmet medical need in hepatocellular... Read more


Tandem Diabetes Care Launches t:slim X2 Insulin Pump Software with Dexcom G7 CGM Integration in U.S.

First Automated Insulin Delivery System in the World to Feature Dexcom’s Most Advanced CGM Technology  SAN DIEGO / Dec 06, 2023 / Business Wire / Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced the launch of updated t:slim X2™ insulin pump software with Dexcom G7 Continuous Glucose Monitoring (CGM) integration in the United States. Tandem’s #1-rated automated insulin delivery (AID) system*... Read more


OrthoPediatrics Announces Launch of Specialty Bracing Division

WARSAW, Ind., Dec. 06, 2023 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, announced the launch of a new division, focused on non-surgical intervention for pediatric orthopedics. The OrthoPediatrics Specialty Bracing division (“OPSB”) will serve as a flagship house of brands and innovative products that expand the Company’s Total... Read more


Bioventus Agrees to Nationwide Contract with Aetna™ Medicare Advantage Plans for DUROLANE® for Knee Osteoarthritis

DURHAM, N.C., Dec. 06, 2023 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, has agreed to a nationwide contract with Aetna™ Medicare Advantage plans. Beginning January 1, 2024, over 3 million Aetna™ Medicare Advantage plan members will have access to DUROLANE to treat knee osteoarthritis (OA) pain. DUROLANE, is a single-injection hyaluronic acid (HA)-based joint-fluid... Read more


Artivion Appoints Lance A. Berry as Executive Vice President, Chief Financial Officer; Announces Retirement of D. Ashley Lee, Chief Financial Officer

Reaffirms Financial Guidance Provided on November 2, 2023 ATLANTA, Dec. 6, 2023 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease today announced the appointment of Lance A. Berry as the Company's Chief Financial Officer, effective as of December 4, 2023. In this role, Mr. Berry joins Artivion's executive leadership team and replaces Mr. D. Ashley Lee, who will retire at the end of the year after a... Read more


EDAP TMS Appoints Lance Willsey, M.S., M.D. to Board of Directors

LYON, France, December 6, 2023 -- EDAP TMS SA (Nasdaq: EDAP) (“the Company” or “EDAP”), the global leader in robotic energy-based therapies, today announced the appointment of Lance Willsey, M.S., M.D. to its Board of Directors. Dr. Willsey replaces Dr. Argil Wheelock who has resigned as director of the Company. “I appreciate the opportunity to join the board of EDAP, where the company’s Focal One Robotic HIFU platform is changing the treatment paradigm... Read more


Axogen Announces Transition of Finance Team Leadership

ALACHUA, Fla. and TAMPA, Fla., Dec. 06, 2023 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced the appointment of Mr. Nir Naor as Chief Financial Officer, effective immediately. A senior finance executive with more than 20 years of experience primarily in the life sciences industry, he replaces Peter Mariani, who will depart Axogen following a brief transition... Read more


NeuroMetrix Announces Peer-Reviewed Publication of Phase 2 Clinical Trial Showing that Quell® Improves Painful Symptoms of Chemotherapy Induced Peripheral Neuropathy (CIPN)

WOBURN, Mass., Dec. 05, 2023 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) noted publication of results from a NIH-funded clinical trial of Quell titled "Wireless transcutaneous electric nerve stimulation (TENS) for chronic chemotherapy-induced peripheral neuropathy (CIPN): a proof-of-concept randomized clinical trial." The paper has been electronically published in The Journal of Pain. The study was a phase 2, multi-site, double blinded, randomized, sham-controlled... Read more


Intelligent Bio Solutions: Leading Pan-European Ferry and Logistics Company, P&O Ferries, Adopts Fingerprint Drug Screening Solution for On-Board, Random Testing of Seafaring Staff

Intelligent Fingerprinting Drug Screening System is expected to reduce P&O Ferries’ overall drug testing costs by 90% Easy-to-use, hygienic fingerprint sweat test improves the testing experience for P&O Ferries employees from previous urine method NEW YORK, Dec. 05, 2023 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing... Read more


Ollie Hinkle Heart Foundation will Introduce Ventripoint's AI-Heart-Imaging Diagnostic Technology to America's Hospitals

Toronto, Ontario – TheNewswire - December 05, 2023 – One of the United States’ leading foundations, the Ollie Hinkle Heart Foundation (OHHF), has selected Ventripoint’s AI-powered heart-imaging technology as one of three artificial intelligence systems it will be presenting to U.S. hospitals. Ventripoint Diagnostics Ltd. ("Ventripoint" or the "Company"), (TSXV:VPT); (OTC:VPTDF) has pioneered an AI technology that transforms ultrasound scans into MRI-quality images... Read more


HeartSciences Receives FDA Confirmation for 510(k) Clearance Pathway

Southlake, TX, Dec. 05, 2023 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (Nasdaq: HSCS; HSCSW) ("HeartSciences" or the "Company"), an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, today announced that it has received confirmation from the FDA to change the clearance pathway for its MyoVista® wavECG™ device and associated AI-ECG algorithm... Read more


NEXGEL Acquires Kenkoderm Psoriasis Skincare Line

Acquisition expands NEXGEL’s health and wellness consumer product portfolio Synergies support optimization of marketing and supply chain operations to drive revenue growth and margins Kenkoderm for the trailing twelve months is profitable and expected to be immediately accretive to NEXGEL LANGHORNE, Pa., Dec. 05, 2023 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of ultra-gentle, high-water-content... Read more


Accuray Initiates Sales of the VitalHold™ Solution in Japan, Supporting Surface-guided Radiation Therapy on the Radixact® System

MADISON, Wis., Dec. 5, 2023 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that the company has initiated sales of the VitalHold™* package supporting surface-guided radiation therapy (SGRT) on the Radixact® System in Japan beginning November 30, 2023. The VitalHold feature incorporates SGRT capability on the Radixact System using the Catalyst+ HD system manufactured by C-RAD, making it possible to deliver deep inspiration breath hold (DIBH)... Read more


Teleflex Awarded Peripheral Access Agreement with Premier

WAYNE, Pa., Dec. 05, 2023 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced it was awarded the Peripheral Access purchasing agreement with Premier, Inc. Effective December 1st, 2023, the new agreement allows Premier members, at their discretion, to take advantage of special pricing and terms pre-negotiated by Premier for Teleflex’s Peripheral Access products. Premier has awarded Teleflex a national... Read more


Mojdeh Poul and Kevin Conroy Join Align Technology Board of Directors

TEMPE, Ariz. & SAN JOSE, Calif. & MADISON, Wis. / Dec 05, 2023 / Business Wire / Align Technology, Inc. (NASDAQ: ALGN) today announced that its Board of Directors has appointed Mojdeh Poul, former EVP and Group President of 3M Health Care, and Kevin Conroy, President, Chief Executive Officer, and Chairman of the Board of Exact Sciences. “I am pleased to welcome Mojdeh and Kevin to Align’s board of directors,” said Joe Hogan, president and CEO of Align Technology.... Read more


NeuroPace to Leverage the Power of its RNS System’s Novel Data Collection, Brain Monitoring and Analysis Capabilities in Groundbreaking Collaboration

First of its kind, multi-year collaboration leverages RNS System’s data to track responses of implanted RNS System patients enrolled in a biotechnology company’s clinical trial In strategic data collaboration, clinical-stage biotechnology company to pay NeuroPace up to $3.7 million over two years to gain non-exclusive access to NeuroPace’s proprietary biomarker monitoring and data analysis capabilities for trial patients MOUNTAIN VIEW, Calif., Dec. 04, 2023... Read more


Becton Dickinson to Present Next Installment of BD Innovates Series: Spotlight on Pharmaceutical Systems

FRANKLIN LAKES, N.J., Dec. 4, 2023 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that it will present the next installment of its BD Innovates series, which will highlight its Pharmaceutical Systems business on Monday, December 11, 2023, at 11:30 am Eastern Time. The BD Innovates series spotlights BD's innovation, products and pipeline in support of its BD 2025 Strategy. The live webcast of... Read more


Merit Medical Systems Announces Proposed Private Placement of $550 Million of Convertible Senior Notes

SOUTH JORDAN, Utah, Dec. 04, 2023 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (Nasdaq: MMSI) (“Merit”), a leading global manufacturer and marketer of healthcare technology, announced today that it intends to offer, subject to market conditions and other factors, $550.0 million aggregate principal amount of Convertible Senior Notes due 2029 (the “notes”) in a private placement (the “offering”) only to persons reasonably believed to be “qualified i... Read more


West Pharmaceutical Receives FDA 510(k) Clearance for Vial2Bag Advanced® 13mm Admixture Device

West expands administration systems portfolio with new smaller size needle-free admixture device for immediate use IV drug transfer designed to maximize the benefits of point-of-care nursing. EXTON, Pa., Dec. 4, 2023 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration systems, today announced FDA 510(k) clearance and launch of its Vial2Bag Advanced® 13mm admixture... Read more


Envoy Medical to Host Fireside Chat Event December 7

Analyst Hosted Event to Feature Comprehensive Discussion of Envoy Medical’s Products, Interviews with Two Study Investigators and Key Opinion Leaders in Cochlear Implants WHITE BEAR LAKE, Minnesota, Dec. 04, 2023 (GLOBE NEWSWIRE) -- Envoy Medical®, Inc. (“Envoy Medical”) (NASDAQ: “COCH”), a revolutionary hearing health company focused on fully implanted hearing systems, today announced that it will host a fireside chat event on Thursday December 7, 2023... Read more


Aurora Spine Announces Newly Published Paper on First 6-month Clinical Evaluation of its ZIP™ Fusion Implant

CARLSBAD, Calif., Dec. 04, 2023 (GLOBE NEWSWIRE) -- Aurora Spine Corporation ("Aurora Spine" or the "Company") (TSXV: ASG) (OTCQB: ASAPF), a designer and manufacturer of innovative medical devices that improve spinal surgery outcomes, today announced the publication of the first 6-month clinical evaluation of its ZIP™ fusion implant in the Journal of Pain Research. Lumbar interlaminar decompression with interspinous fixation is an established safe and effective treatment... Read more


Senhance Robotic System Sold by Asensus Surgical

RESEARCH TRIANGLE PARK, N.C., Dec. 04, 2023 (GLOBE NEWSWIRE) -- Asensus Surgical, Inc. (NYSE American: ASXC), a medical device company digitizing the interface between the surgeon and patient, announced that a Senhance® Surgical System has been sold to the Company’s distribution partner and will be placed in a hospital in the Commonwealth of Independent States region. This marks the second system sold to the region in the past month. “We are excited to be partnering... Read more


NanoVibronix Enters into Letter of Intent with APOGEPHA Arzneimittel GmbH to Explore European Distribution Opportunity

Independent Urology Company to Study the Potential for UroShield Distribution in Germany and other European Markets ELMSFORD, N.Y. / Dec 04, 2023 / Business Wire / NanoVibronix, Inc. (NASDAQ: NAOV), a medical device company that produces the UroShield®, PainShield® and WoundShield® Surface Acoustic Wave (SAW) Portable Ultrasonic Therapeutic Devices, today announced that it has entered into a non-binding letter of intent (the “LOI”) with APOGEPHA Arzneimittel GmbH... Read more


RetinalGeniX Technologies Appoints Dessy Boneva, MD, FACS to the Board of Directors

PETALUMA, Calif., Dec. 04, 2023 (GLOBE NEWSWIRE) -- RetinalGeniX Technologies Inc. (OTCQB: RTGN) (“RetinalGeniX” or the “Company”), today announced that Dessislava (Dessy) Boneva, M.D. has joined the Company’s Board of Directors. RetinalGeniX is an ophthalmic research and development med-device and therapeutic drug development company focused on developing High-Resolution Retinal Imaging and Pharmaco-Genetic Mapping™ technologies. Dr. Boneva is an experienced... Read more


STRATA Skin Science Announces Strengthening of Leadership Team

Shmuel Gov Promoted to Chief Operating Officer Dr. Amandeep Kaur Hired as Vice President of Marketing and Business Growth HORSHAM, Pa., Dec. 04, 2023 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing and marketing innovative products for the treatment of dermatologic conditions, today announced the promotion of Shmuel Gov to Chief Operating Officer. The Company has also hired Dr.... Read more


Lilian Zhou Appointed to STAAR Surgical Board of Directors

LAKE FOREST, Calif. / Dec 04, 2023 / Business Wire / STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (ICL) for myopia, astigmatism and presbyopia, today announced the appointment of Lilian Zhou to its Board of Directors, effective December 4, 2023. “We welcome Lilian Zhou as a new member to our Board of Directors. Lilian is an accomplished investment portfolio manager who worked at... Read more


Nevro Announces Acquisition of Vyrsa™ Technologies

Refinances with $200M Structured Debt Maturing in 2029 REDWOOD CITY, Calif., Nov. 30, 2023 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced that it has acquired Vyrsa Technologies ("Vyrsa"), a privately held medical technology company focused on a minimally invasive treatment option for patients suffering from chronic sacroiliac joint... Read more


Sanara MedTech Announces the Publication of a 5,335 Patient Study Demonstrating a Significant Reduction in Surgical Site Infections When Activated Collagen (CellerateRX® Surgical Powder) Was Used to Promote...

FORT WORTH, TX, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Sanara MedTech Inc. Based in Fort Worth, Texas, Sanara MedTech Inc. (“Sanara,” the “Company,” “we,” “our” or “us”) (NASDAQ: SMTI), a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical, chronic wound and skincare markets, announced today that the Journal of Surgery has published... Read more


Leading Specialist Material Handling Company, Titan Cranes and Rigging Pty Ltd., Adopts Intelligent Bio Solutions Fingerprinting Drug Screening System

NEW YORK, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (NASDAQ: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced that Titan Cranes and Rigging Pty Ltd. ("Titan") has adopted the Company's unique Intelligent Fingerprinting Drug Screening System. Since 2001, Titan has secured its spot as Australasia’s leading specialist material handling company, providing... Read more


Helius Medical Technologies to Present at NobleCon19 Annual Conference

NEWTOWN, Pa., Nov. 30, 2023 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today announced that Dane Andreeff, President and Chief Executive Officer, will present at the NobleCon 19th Annual Emerging Growth Equity Conference as follows: Date: Tuesday, December 5, 2023 Time: 2:00pm E... Read more


Becton Dickinson Launches Advanced Vascular Access Ultrasound System Designed to Improve Clinician Efficiency

SiteRite™ 9 Ultrasound System Delivers Enhanced Image Quality and Vessel Assessment Tools to Aid in First Attempt IV Insertion Success FRANKLIN LAKES, N.J., Nov. 30, 2023 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today launched a new, advanced ultrasound system designed to help improve clinician efficiency when placing peripherally inserted central catheters (PICCs), central venous catheters, IV... Read more


KKR, Hologic and Ajax Health Create New Platform to Accelerate Medical Device Innovation

Platform Will Focus on Technologies to Detect Lung Cancer, the Leading Cause of Cancer Deaths NEW YORK & MARLBOROUGH, Mass. / Nov 30, 2023 / Business Wire / KKR, a leading global investment firm, today announced a new platform established with investments from KKR and Hologic, Inc. (Nasdaq: HOLX), a global leader in women’s health and medical technology innovator. The new platform, named Maverix Medical, will be managed by Ajax Health under the leadership of Duke... Read more


Monogram Orthopaedics to Host Robotic Product Demo Live Stream on Thursday, December 14, 2023 at 11:00 a.m. Eastern Time

Demo will feature Monogram's mBôs commercial robot with teaser AUSTIN, TX / ACCESSWIRE / November 30, 2023 / Monogram Orthopaedics Inc. (NASDAQ:MGRM) ("Monogram" or the "Company"), a medical technology company focused on reconstructive joint procedures and surgical robotics, will host a live stream product demonstration of features of its commercial robot on Thursday, December 14, 2023, at 11:00 a.m. Eastern Time. Please use the link below to register. Monogram... Read more


Femasys Announces the Appointment of James Liu, M.D., as Chief Medical Officer

ATLANTA, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a biomedical company focused on meeting significant unmet needs for women worldwide with a broad portfolio of in-office, accessible solutions, including a lead, late-clinical stage product candidate and innovative therapeutic and diagnostic products, today announced the appointment of James Liu, M.D., as Chief Medical Officer. Dr. Liu joins Femasys as the company accelerates commercialization of its... Read more


CooperCompanies Appoints Lawrence E. Kurzius to Board of Directors

SAN RAMON, Calif., Nov. 30, 2023 (GLOBE NEWSWIRE) -- CooperCompanies (Nasdaq: COO) announced today that its Board of Directors has appointed Lawrence E. Kurzius as an independent director, effective December 1, 2023. Kurzius has also been appointed to serve on the Audit Committee and Organization & Compensation Committee when he joins the Board. “We are thrilled to welcome Lawrence to our Board of Directors,” said Al White, President and CEO. “His track record... Read more


Outset Medical to Present at BofA Home Care Conference

SAN JOSE, Calif. / Nov 29, 2023 / Business Wire / Outset Medical, Inc. (Nasdaq: OM) (“Outset”), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today announced that members of management will participate in a virtual panel discussion at the BofA Securities Home Care Conference on Monday, December 4, 2023, at 12:00pm PT / 3:00pm ET. The panel discussion will include Leslie Trigg, Outset’s Chair and... Read more


Inspira Technologies Collaborates with Ennocure for development of a Proprietary Bio-Electronic Treatment to Prevent Associated Bloodstream Infections in ICU Patients

RA'ANANA, Israel, Nov. 29, 2023 /PRNewswire/ -- Inspira Technologies OXY B.H.N. Ltd. (Nasdaq: IINN) (Nasdaq: IINNW) (the "Company" or "Inspira"), an innovator in life support technology, is excited to announce a partnership with Ennocure MedTech Ltd. At the core of Inspira's mission is a groundbreaking approach to oxygenate blood directly to replace life support mechanical ventilation. Inspira seeks to include bio-electronic technology as part of the INSPIRA... Read more

COPYRIGHT ©2023 HEALTH STOCKS HUB